?> Contact us Follow Us
Biosimilars Forum
  • About Us
    • Members
    • Executive Director
  • Why Biosimilars
    • The Issue
    • Our Solutions
  • Biosimilars 101
    • Foundations
    • Core Principles
    • FDA Regulatory Tenets
    • Biosimilars FAQs
    • Future Evolution of Biosimilar Development
    • Approved Biosimilars
  • Advocacy
    • Our Action
    • Tools
  • News
  • Resources
  • Get Involved
    • Partners

signalgroup

Get more out of your business.
Reach it with Microsoft Dynamics 365 Business Central.
News
June 21, 2022 signalgroup
Rachel Turow Member Spotlight
News
June 16, 2022 signalgroup
Brian Lehman Member Spotlight
News
June 7, 2022 signalgroup
The Biosimilars Forum Commends FTC for Probe into PBMs
News
June 6, 2022 signalgroup
Biosimilars Forum Welcomes Fresenius Kabi
Member Spotlight
May 17, 2022 signalgroup
Tiffany Fletcher Member Spotlight
News
April 6, 2022 signalgroup
Biosimilars Forum Letter to Senate HELP Committee on FDA User Fee Agreements
News
March 31, 2022 signalgroup
HHS Inspector General Report: Biosimilars Could Generate Significant Medicare Part D Savings
News
March 9, 2022 signalgroup
Biosimilars Forum Executive Director to Discuss Current Biosimilars Landscape at World Biosimilars Congress
News
March 2, 2022 signalgroup
The Biosimilars Forum Calls on President Biden to Incentivize Biosimilars to Lower Prescription Drug Costs
News
March 1, 2022 signalgroup
Biosimilars Forum Welcomes HHS Inspector General Study on Biosimilars in Medicare Part B
  • Prev page
  • 03
  • 04
  • 05
  • 06
  • 07
  • Next page

  • Biosimilars 101
  • Biosimilars FAQs
  • Advocacy
  • Stay Connected
Biosimilars Forum
© 2025 Biosimilars Forum. All rights reserved.
  • Terms of Use
  • |
  • Privacy Policy
  • |
  • Contact Us